Introduction: Dexmedetomidine (Dex) has sedative, analgesic, and anesthetic-sparing
INTRODUCTION
Dexmedetomidine (Dex) is a short-acting a2-adrenoceptor agonist commonly used in adult anesthesia and intensive care [1] [2] [3] . It provides analgesia, preserves the ability to be roused, and avoids respiratory depression [3] . Several studies suggest that Dex can be useful in 
METHODS
This meta-analysis is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
Bibliographic Search and Analysis
We conducted this meta-analysis according to the guidelines of the Cochrane Handbook for Systematic Reviews [8] of intervention and the PRISMA statements [9] . Literature databases The following queries were used to discard irrelevant results related to postoperative Dex use: ''Dexmedetomidine'' and ''children or child or infant or infants''. No language restriction was applied for searches. In addition, a manual search of the references found in all selected articles was performed, including reviews and meta-analyses. In order to confirm results of our meta-analysis on the primary outcome, a second set of analyses were performed using the trial sequential method [16, 17] . This statistical method allows combining effects of studies and previous meta-analysis performed on the same subject to correct results (the adjustment of alpha-risk related to multiple comparison in previous meta-analyses), predict the possibility of a significant result in case of low power of the actual analysis and estimates the effect-size to be included in a meta-analysis (termed the information size for meta-analysis) to find a significant result. This analysis was performed on the freeware Copenhagen Trial Unit's Trial Sequential Analysis Software, hereafter: TSA Software, Copenhagen, Sweden.
In studies with more than one intervention arm, in order to take into account all data, each arm was considered as a study and compared to the control group. However, given the weight taken by those studies in overall results, a sensitivity analysis was performed by removing one arm and another in order to assess the effect of these studies on outcome. Finally, to avoid calculation failure related to zero values in RevMan and TSA, a 1 or 0.001 was added to all groups when the number of events was equal to 0 in one group (for RevMan and TSA, respectively).
Statistical methods are available to assess the effects of unpublished studies on meta-analysis results (publication bias). Publication bias is assessed by studying the distribution of results on a funnel plot, which is a scatter plot of the intervention effect (RR, MD, or SMD) estimates from individual studies against some measure of each study's size or precision (standard error of the intervention effect). Funnel plot asymmetry may indicate that some studies went unpublished [18, 19] . This asymmetry can also indicate result heterogeneity or poor methodology in included studies [18, 19] . According to the Cochrane collaborative guideline [8] , it is suitable to assess publication bias when analysis aggregates at least ten studies.
Results are expressed as RR, MD, or SMD (95% confidence interval), I
2 , p value for I 2 statistics.
RESULTS

Study Selection and Features
Using the above-described criteria, 545 pediatric studies were found. Analysis allowed the selection of 81 relevant randomized controlled studies. Among these articles, 67 were discarded for at least one of the following reasons: no pain or analgesic data: 20, data not displayed: one, data expressed as interquartile range (IQR): four without a response from authors, not controlled with placebo: four, association with other compounds (ketamine): one, not administered intraoperatively: 31, neurosurgery: one, cardiac surgery: two, adult trials: two and abstract: one.
Characteristics of Included Studies
Analyses were carried out upon 14 articles [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] (Table 1) . There was no difference in recorded information between assessors and no second analysis was necessary. All studies were performed during surgery (no anesthesia for procedural sedation). Surgery performed consisted of: adenotonsillectomy and outpatient surgeries ( Table 1 ). The selection process is summarized in Fig. 1 and characteristics of included studies are displayed in Table 1 . Three studies contained three arms (two groups including patients treated with Dex compared to one control group): the study performed by Ghai and collaborators [23] (both arms using a bolus of Dex), the one performed by Meng and collaborators [28] (both using a bolus mode) and the study performed by Pestieau and collaborator [30] (using either a bolus or a continuous infusion). Postoperative pain intensities were expressed as median (range) in four studies [23, 24, 27, 32] and necessity transformation to mean and SD. Finally, both primary and secondary outcomes interested the PACU period and no data in studies described outcomes after this period.
Overall Results
Seven hundred and seventy patients received Dex 
Subgroup Analyses
Subgroup analyses were carried on the following criteria: adenotonsillectomy versus outpatient surgery, bolus administration of Dex versus continuous administration and low-dose bolus versus high-dose bolus. High and low median bolus were chosen according to the median value of boluses used in studies (0.5 lg/kg), accordingly, low bolus doses were \0.5 lg/kg and high bolus doses were C0.5 lg/kg. Dex was still found to decrease both postoperative opioid consumption ( Fig. 3a-c) and postoperative pain intensity (Fig. 4a-c) except after adenotonsillectomy and when boluses were \0.5 lg/kg irrespective to the presence or absence of a continuous administration (Figs. 3a, 4a) . However, subgroup analyses interaction did not find a significant difference between paired subgroups for all outcomes (Figs. 3, 4) .
Effect of Study's Bias on Results
Including in the analysis studies with low-bias risks, found Dex effective in decreasing opioid However, given the low number of studies of low-bias included in this meta-analysis for primary outcome, we performed a trial sequential analysis (TSA) including studies expressed as discrete data (nine studies on overall 12 available [21] [22] [23] [24] [25] [26] [27] [28] 31] for the primary outcome because no inverse variance method is available in the TSA software) and data of low-bias risk studies to compute the relative risk reduction in order to determine the number of patients needed to found a significant result [16, 17] . (Fig. 5 ). This analysis also found the number of patients to be included in this meta-analysis with an alpha risk of 5 % and a power of 80 % to detect a relative risk reduction of 34 % of 525 patients (Fig. 5a) . Finally, introducing a correction for previous analysis [5] , found Dex to continue exhibiting a significant opioid-sparing effect (Fig. 5b) . The cumulative results of RevMan and TSA analyses clearly indicate that the opioid-sparing effect of Dex is valid assumption during pediatric surgery.
Publication Bias Analyses
Concerning publication bias, according to
Cochrane recommendations (see Methods section for publication bias), two outcomes were examined, namely, opioid consumption and postoperative pain and. Both funnel plots ( Fig. 6a and c Forest plot of meta-analysis of the effects of dexmedetomidine versus placebo on postoperative nausea and vomiting in the PACU. The square in front of each study (first author and year of publication) is the RR for individual trials, and the corresponding horizontal line is the 95% CI. The lozenge at the bottom represents pooled OR with 95% CI. Studies with more than one Dex arm are displayed as author, name, year of publication_1, and author name year of publication_2 (see Table 1 for exact description of each arm). CI confidence interval, Dex dexmedetomidine, OR odds ratio, PACU postanesthesia care unit, RR risk ratio, SE standard error, SMD standardized mean difference Interestingly, doses used in included studies ranged from 0.3 to 2 lg/kg (median of 0.5 lg/ kg) and continuous administration during the intraoperative period ranged from 0.2 to 0.7 lg/ kg/h (median of 0.2 lg/kg/h). These doses were lower than those commonly used during procedural sedation (especially during pediatric imaging: bolus of 1 lg/kg and continuous infusion of 0.5-2 lg/kg/h) [38] . This difference is logical given that during painful procedures, Dex is used in combination with other opioid and hypnotic agents while imaging requires sedation that can be achieved using Dex as the sole anesthetic agent. Our results indicate that optimal bolus dose of Dex to produce its analgesic and opioid-sparing effects must be C0.5 lg/kg. Although, this interesting finding had to be further explored, this result gives an interesting indication on the optimal dose of Dex to be used to improve postoperative pain management.
b Fig. 3 Forest plot of subgroup analysis of the effect a of the surgery, b of the bolus mode versus the bolus plus continuous mode, and c the effect of a bolus of C0.5 lg/kg versus a bolus \0.5 lg/kg, on Dex opioid-sparing effect in the postanesthesia care unit. The square in front of each study (first author and year of publication) is the RR for individual trials, and the corresponding horizontal line is the 95% CI. The lozenge at the bottom represents pooled OR with 95% CI. The test for subgroup difference represents the interaction test between groups. Studies with more than one Dex arm are displayed as author name, year of publication_1, and author name, year of publication_2 (see Table 1 for exact description of each arm). CI confidence interval, Dex dexmedetomidine, RR risk ratio, SE standard error decrease postoperative opioid administration [40] . This allows a rapid switch from the intravenous administration of those compounds (often administered via a patientor nurse-controlled analgesia) to an oral administration of non-opioid analgesics [40, 41] . This accelerates the discharge from the hospital while most surgical care can be performed at home. In addition, decreasing the amount of morphine has been shown to decrease opioid-related side effects such nausea, vomiting, and constipation; and decrease the time of first oral intake, even after abdominal surgery. Altogether, results of this meta-analysis strongly encourage studies on the effects of Dex on rapid postoperative rehabilitation.
Limitations of the Study
This meta-analysis suffers many limitations. The primary outcome of the current meta-analysis (postoperative opioid consumption) was the primary outcome of only two individual trials ( Table 1) . As a consequence, most data were computed with secondary outcomes of individual studies. However, using the trial sequence analysis allow to confirm our results and the adequate patients included in this meta-analysis. Data from studies designed with more than one active group were analyzed with each arm considered as a separate study. Although this would increase the weight of the considered study in the analysis, this allowed avoiding publication bias.
Subgroup analyses were performed with the aim of reducing heterogeneity and to identify factors influencing results. However, this goal was not achieved for most outcomes. This probably explains the absence of statistical difference between subgroups (interaction test) even when showing different results on outcomes. Consequently, our results must be interpreted cautiously, especially for outcomes involving lesser numbers of analyzed studies.
Using funnel plots, we demonstrated suspected publication bias for two outcomes-pain intensity in PACU and postoperative opioid consumption in PACU-indicating that some studies of these outcomes with negative results
were not published. Alternatively, this funnel plot asymmetry might also result from the great heterogeneity between studies.
The current meta-analysis was designed to examine the postoperative effects of Dex versus placebo during pediatric surgery. As such, no b Fig. 4 Forest plot of subgroup analysis of a the surgery, b the bolus mode versus the bolus plus continuous mode, and c the effect of a bolus of Dex C0.5 lg/kg versus a bolus \0.5 lg/kg, on Dex effect on postoperative pain intensity in the postanesthesia care unit. The square in front of each study (first author and year of publication) is the SMD for individual trials, and the corresponding horizontal line is the 95% CI. The lozenge at the bottom represents pooled OR with 95% CI. The test for subgroup difference represents the interaction test between groups. Studies with more than one Dex arm are displayed as author name, year of publication_1, and author name year of publication_2 (see Table 1 for exact description of each arm). CI confidence interval, Dex dexmedetomidine SE standard error, SMD standardized mean difference conclusions can be made about the efficacy of Dex in comparison to other sedative or analgesic agents such as morphine. Our study is also limited regarding the effects of Dex on intraoperative hemodynamics. This outcome was excluded from our meta-analysis for the following reasons: heterogeneity in numerical expression of this outcome, heterogeneity in types of surgery and Dex infusion regimes, which could all result in hemodynamic disturbances, and the absence of an exhaustive search for articles displaying this outcome.
Finally, due to the design of the included studies, no data for postoperative analgesia are available after discharge from the PACU. This represents the most challenging point for future studies.
CONCLUSIONS
Our meta-analysis shows that intraoperative Dex, when compared to placebo, is associated with reduced in postoperative opioid consumption and an improvement of pain management during PACU stay. More studies are necessary to assess the dose-effect of Dex on postoperative pain management and its benefice during longer postoperative period in order to precise its advantages during rapid postoperative rehabilitation programs.
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